Pharmaceuticals, Biotechnology and Life Sciences
ObsEva has completed recruiting patients for its Phase 3 clinical trial PRIMROSE 1 testing of oral gonadotropin releasing hormone (GnRH) receptor antagonist linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).
Lannett Company has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc., a wholly owned subsidiary of privately held Neolpharma Pharmaceutical Group.
Astrazeneca has entered partnership with the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) named the Lung Ambition Alliance, to try to eliminate lung cancer as a cause of death.
The U.S. FDA has granted accelerated approval to Karyopharm Therapeutics’s Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of certain adult patients with relapsed refractory multiple myeloma (RRMM).
– ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS® (eculizumab) –
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA).
EnPro Industries, Inc. (NYSE: NPO), a leading manufacturer of engineered industrial products, today announced it has acquired The Aseptic Group (comprising Aseptic Process Equipment SAS and Aseptic Services SARL), a privately-held company which distributes, designs and manufactures aseptic fluid transfer products for the pharmaceutical and biopharmaceutical industries.
Novocure announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open.
FSD acquires platform company to advance R&D of targeted application of micro-Palmitoylethanolamide impacting the human endocannabinoid system
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.